Ozempic Digestive Side Effects: What to Expect

About 1 in 8 American adults is currently taking a GLP-1 drug like Ozempic, Wegovy, Mounjaro, or Zepbound, and roughly 18% have tried one at some point (KFF Health Tracking Poll). Most of them end up with some form of digestive disruption. That's not a small-print side effect. In the pivotal STEP 1 trial of semaglutide, 74% of participants reported a gastrointestinal event at some point during treatment.

Here is what actually happens inside your gut when you start a GLP-1, the specific symptoms the clinical trial data predict, how long they tend to last, and what works to manage them.

Why GLP-1 Drugs Disrupt Digestion

GLP-1 (glucagon-like peptide-1) is a hormone your gut releases after you eat. Semaglutide, tirzepatide, and liraglutide are synthetic versions that bind the same receptor but hang around much longer. The clinical effect most people notice is appetite suppression. The mechanism behind that effect is what causes the digestive side effects.

GLP-1 receptors sit in the myenteric plexus, the enteric nervous system that controls gut motility. When these drugs activate those receptors, they slow down two things at once: how fast food leaves the stomach (gastric emptying) and how fast it moves through the rest of the digestive tract (whole-gut transit). A 2024 review in the Journal of Clinical Endocrinology & Metabolism found delayed gastric emptying in roughly 80% of patients on GLP-1 therapy, and delayed whole-gut transit in 44%.

That delay is the whole point. It's what makes you feel full on less food. But the same mechanism that shrinks your appetite also parks partially digested food in your stomach for longer, and that's the reason nausea, early fullness, reflux, and constipation dominate the side effect profile.

The Numbers from the Clinical Trials

The STEP 1 trial published in the New England Journal of Medicine enrolled 1,961 adults with overweight or obesity and gave them either semaglutide 2.4 mg (Wegovy's dose) or placebo for 68 weeks. A pooled tolerability analysis from the STEP 1, 2, and 3 trials published in Diabetes, Obesity and Metabolism broke down the specific numbers:

• Nausea: 44.2% on semaglutide vs. 17.8% on placebo
• Diarrhea: 31.5% vs. 15.9%
• Vomiting: 24.8% vs. 6.6%
• Constipation: 23.4% vs. 10.9%
• Abdominal pain: 20.4% vs. 10.3%

For the lower diabetes doses (Ozempic 0.5-1 mg), the SUSTAIN trials logged any GI adverse event in about 32.7% to 36.4% of patients versus 15.3% on placebo (Ozempic FDA prescribing information). The takeaway: symptoms scale with dose.

Here's the part that usually gets buried. 99.5% of those GI events were non-serious and 98.1% were mild to moderate. Only 4.3% of semaglutide participants discontinued the drug because of GI side effects, compared to 0.7% on placebo. Unpleasant, yes. Dangerous for most people, no.

Nausea: The Headline Symptom

Nausea is both the most common GLP-1 side effect and the one most likely to get someone to quit. The intensity tracks with dose escalation, which is why every GLP-1 uses a slow titration schedule starting at 0.25 mg for semaglutide and working up to the target dose over 16+ weeks.

In the pooled STEP analysis the median duration of a nausea episode was 8 days, vomiting 2 days, diarrhea 3 days. Most episodes occurred in the first 20 weeks and tapered off as patients reached their maintenance dose.

What reliably helps:

• Eat smaller meals. Your stomach is emptying slower. Stuffing it past a small serving is the fastest route to nausea. Half your usual portion is a reasonable starting point.
• Cut fat. High-fat meals sit in the stomach longer than carbs or lean protein, which amplifies every symptom. The Cleveland Clinic specifically flags fried food, heavy sauces, and ultra-processed snacks as the worst offenders.
• Stay upright for 30+ minutes after eating. Lying down lets stomach contents push back up, which drives reflux and nausea.
• Hydrate between meals, not during. Fluids mixed into a big meal worsen the full feeling.
• Avoid alcohol during titration. It irritates an already slow stomach.

If nausea is severe or not resolving, your prescriber can hold or lower the dose. That usually fixes it within a week.

Constipation: The Long Tail Symptom

Constipation is where GLP-1s behave differently. The STEP pooled data showed a median constipation duration of 47 days on semaglutide versus 35 days on placebo. Unlike nausea, it doesn't reliably resolve on its own. It tends to persist for as long as you're on the drug because it's a direct downstream effect of slowed colonic transit.

If stools are turning into Bristol Type 1 or 2 (hard lumps, pellet-shaped, difficult to pass), that's the mechanism on display. The colon has extra time to pull water out of waste, and the result is drier, harder stool. Our Bristol Stool Chart guide breaks down the seven types and what each says about transit time.

What works for GLP-1 constipation:

• Water. Aggressively. Cleveland Clinic recommends 91 to 125 ounces of fluid per day for adults on GLP-1s, which is more than most people drink without prompting.
• Soluble fiber. Psyllium husk (Metamucil) at 5-10 g/day has the strongest evidence for softening stool and speeding transit (systematic review, 2014). Ramp up slowly; too much too fast creates gas.
• Magnesium. Magnesium citrate or magnesium oxide draws water into the colon. 200-400 mg at bedtime is a common starting dose.
• Movement. Even a 10-15 minute walk after meals meaningfully increases motility.
• Osmotic laxatives. Polyethylene glycol (MiraLAX) is safe for daily use and effective when fiber and fluids aren't enough.

We went deeper on each of these in our constipation remedies guide, which ranks every intervention by the strength of its evidence.

Bloating, Reflux, and "Sulfur Burps"

Delayed gastric emptying doesn't just cause nausea. It also creates a sensation of persistent fullness, visible abdominal distension, and upper GI symptoms most people don't expect:

• Bloating and distension from fermentation of food that's hanging around too long. Our guide to what causes bloating covers the broader picture, but GLP-1-related bloating specifically responds to the same dietary fixes as the nausea: smaller meals, less fat, less carbonation.
• Acid reflux and heartburn because food is sitting in the stomach instead of moving on. A 2022 pharmacovigilance analysis of the FDA Adverse Event Reporting System found GERD and related reflux signals disproportionately reported with semaglutide.
• "Sulfur burps" with a rotten-egg smell. These come from hydrogen sulfide gas produced as protein and fat sit in the stomach longer than usual. They're unpleasant but benign.

Diarrhea: Less Common, Usually Brief

Roughly 30% of STEP 1 participants had diarrhea at some point, but episodes were short (median 3 days) and often coincided with dietary changes, not drug toxicity. GLP-1s themselves tend to slow transit, so persistent diarrhea usually points elsewhere: bile acid malabsorption, a recent dietary shift toward high-sugar or high-sugar-alcohol foods, or an unrelated infection.

If diarrhea lasts more than a few days, log what you're eating. Common triggers get obvious fast when you track. Our IBS food triggers article covers the same hit list that tends to cause GLP-1 diarrhea too, since the underlying mechanism (visceral sensitivity plus altered motility) overlaps.

The Serious Risks

Most GLP-1 side effects are uncomfortable, not dangerous. A small number are the other way around.

Gastroparesis. Severe delayed gastric emptying can become persistent. In September 2023 and again in January 2025, the FDA updated the Ozempic label to include warnings about severe gastrointestinal reactions, and noted that semaglutide is not recommended in patients with severe gastroparesis (FDA prescribing information, 2025).

Bowel obstruction and ileus. The FDA added an ileus warning to the Ozempic label in September 2023. A 2023 JAMA analysis of a health claims database reported a roughly 4.2-fold higher risk of intestinal obstruction among GLP-1 users compared to a non-GLP-1 weight loss drug. Absolute incidence is still low, but the signal is real.

Pancreatitis. The same JAMA study estimated a 9-fold higher risk of acute pancreatitis versus the comparator drug. Severe, steady upper-abdominal pain that radiates to the back, especially with vomiting, needs emergency evaluation.

Gallbladder disease. Rapid weight loss plus GLP-1-specific effects on bile concentration raise the risk of gallstones and cholecystitis. This shows up most often 3-6 months in.

When to Call Your Prescriber

Most GI symptoms on a GLP-1 can be managed with a dose adjustment and dietary changes. The exceptions:

• Severe or persistent abdominal pain, particularly if it radiates to the back
• Inability to keep liquids down for 24+ hours
• Signs of dehydration (dark urine, dizziness, tachycardia)
• Black tarry stool or visible blood
• No bowel movement for more than 5 days despite fluids, fiber, and OTC laxatives
• Sudden severe bloating with abdominal distension and vomiting (possible obstruction)

How Tracking Actually Helps

GLP-1 side effects move in patterns. They flare after every dose escalation, often peak 2-3 days after injection, and shift with diet. When you track, three things become obvious fast: which foods reliably trigger symptoms, how your stool form is trending on the Bristol scale, and whether a dose bump is worth pushing through or worth slowing down.

That data is also what your prescriber wants. "I'm constipated" is vague. "Over the last 21 days I've had bowel movements on days 1, 4, 7, 10, 13, 17, 20, averaging Bristol Type 2" is something a doctor can act on.